Correspondence: In Kyoon Lyoo, MD, PhD, MMS, Department of Psychiatry and Interdisciplinary Program in Neuroscience, Seoul National University College of Medicine and College of Natural Sciences, 28 Yongon-dong, Jongno-gu, 110-744 Seoul, South Korea (inkylyoo@gmail.com).
Submitted for Publication: September 5, 2010; final revision received and accepted January 5, 2011.
Author Contributions: Drs Lyoo and Kim contributed equally to this work. Drs Lyoo, Kim, Yoon, and Hwang had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Financial Disclosure: Dr Lyoo reports receiving research support from Eli Lilly and Company and Lundbeck.
Funding/Support: This work was supported by grant 2010K000814 from the Brain Research Center of the 21st Century Frontier Research Program funded by the Korean Ministry of Education, Science and Technology; by grant KRF-2008-220-E00021 funded by the National Research Foundation of Korea; and by an independent investigator award from the National Alliance for Research on Schizophrenia and Depression.
Role of the Sponsors: The funding sources had no role in the design and conduct of the study; in the collection, management, analysis and interpretation of the data; or in the preparation, review, or approval of the manuscript.
Previous Presentation: This study was presented in part at the Frontier Tech Fair of the Korean Ministry of Education, Science and Technology; November 2, 2009; Seoul, South Korea.
Additional Contributions: We acknowledge the invaluable contributions of the participants of this 5-year longitudinal follow-up study. Hyeonseok S. Jeong, BS, and Han Byul Cho, BS, provided technical assistance; Emily Kim, English language editing as a native speaker; and Perry F. Renshaw, MD, PhD, thoughtful insights and valuable discussions.